KHN705 / Chengdu Kanghong Pharma - LARVOL DELTA

Broad-spectrum antitumor activity of the biosynthetically derived molecule KHN705 (AACR 2026) - P2 | "We previously developed KH617, a small molecule targeting tumor metabolic reprogramming, via biosynthetic technology...KHN705 exhibited comparable efficacy to single-agent chemotherapy across a wide range of human cancer types, including gastric, hepatocellular, lung, and brain cancers, supporting its further development for treating diverse malignancies. In Vitro: IC50 values were determined against 14 human cancer cell lines (acute myeloid leukemia; colorectal cancer [cisplatin- and 5-FU-resistant variants]; lymphoma; bladder cancer; breast cancer; gastric cancer; prostate cancer; endometrial cancer; thyroid cancer; esophageal cancer; cervical cancer; brain cancer; renal cell carcinoma; lung cancer) following a 72-hour incubation...Mice received vehicle or drug (KHN705, paclitaxel, regorafenib, pemetrexed sodium, temozolomide) for durations ranging from 16 to 28 days... We report the first demonstration of KHN705's anti-tumor activity, enabled by our..."

Late-breaking abstract • Acute Myelogenous Leukemia • Bladder Cancer • Brain Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Lymphoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma